Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Head & Neck 1Gastrointestinal 1

Conditions

Stomach Neoplasms 1Lymphoproliferative Disorders 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma 1Hodgkin Disease 1Head and Neck Neoplasms 1

Interventions

Oxaliplatin 4Paclitaxel 3Capecitabine 3pembrolizumab 2fludarabine 2Trastuzumab 2S 1 (combination) 2Ramucirumab 2Polymerase Chain Reaction 2Irinotecan 2Gastric Bypass 2Fluorouracil 2Cyclophosphamide 2Biopsy 2zimberelimab 1tusamitamab ravtansine 1talazoparib 1relatlimab 1olaparib 1milademetan 1atezolizumab 1apatinib 1XELOX 1Valganciclovir 1Taxes 1Saline Solution 1Nivolumab 1Methods 1Lubricant Eye Drops 1Lidocaine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Stomach Neoplasms × 4-phenylbutyric acid × Clear all
NCT00387530 2019-08-02

Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer

University of California, San Diego

Phase 2 Withdrawn
GastrointestinalHead & NeckLymphoid

Head and Neck Neoplasms, Hodgkin Disease, Lymphoma, Lymphoproliferative Disorders, Stomach Neoplasms, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡